European Leukemia Trial Registry
Trial: AmBiGuard Studie

More Details
Title Randomized Phase 3 Study of Prophylactic Liposomal Amphotericin B for the Prevention of Invasive Fungal Infections in the Remission-Induction Chemotherapy for ALL
Scientific Title A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)
Short Title AmBiGuard Studie
Trialgroup NN
Type of Trial multicentric, randomized, double-blind
Disease Acute lymphoblastic leukemia(ALL) Supportive Care
Age >= 18 years
Status Closed
Start of Recruitment 01.08.2011
Leader Cornely, Prof. Dr., Oliver A.
Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 14.09.2011 Johannes Kraus
changed 20.03.2015 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org